Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants

Summary

This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults (18-50 of age inclusive), and single dose in healthy elderly (51-75 of age inclusive). The effects of dosing with or without food in healthy adults will also be studied (optional).

Timeline

Start

2023-01-20

Primary completion

2026-06-02

Completion

2026-07-01

Drugs

Indications